Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma

NCT02270034 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.

NCT NCT02270034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02270034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Grupo Español de Investigación en Neurooncología
Phase
Phase 1
Overall status
Completed
Start date
August 13, 2014
Completion date
October 26, 2020
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme (grade iv) of cerebellum